Turning Point Brands (TPB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on May 8, 2025, with stockholders able to participate and vote online using a control number from their proxy card.
Key proposals include electing ten directors, amending the Certificate of Incorporation to limit officer liability, ratifying KPMG LLP as the new independent auditor, and an advisory vote on executive compensation.
Only stockholders of record as of March 7, 2025, are entitled to vote; 17,867,759 shares are outstanding, with a quorum set at 8,933,880 shares.
The Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposals: election of ten directors, amendment to limit officer liability, ratification of KPMG LLP as auditor, and advisory say-on-pay vote.
The amendment to limit officer liability aligns with recent Delaware law changes and aims to attract and retain qualified officers.
KPMG LLP is proposed as the new auditor, replacing RSM US LLP, to ensure continued independence and meet evolving company needs.
Shareholder proposals for the 2026 meeting must be submitted by November 24, 2025, to be included in the proxy statement.
Board of directors and corporate governance
The Board is expanding from nine to ten members, with Kathleen Shanahan nominated for the new seat.
The Board includes a mix of experienced executives, with a majority self-identifying as women or people of color.
Board leadership is separated between the Executive Chairman and CEO, with a Lead Independent Director ensuring independent oversight.
Three standing committees: Audit, Compensation, and Nominating & Governance, all composed of independent directors.
Directors receive annual cash retainers and RSUs; additional fees are paid for committee roles.
Latest events from Turning Point Brands
- Modern Oral net sales jumped 266%, driving 29% overall revenue growth and strong 2026 outlook.TPB
Q4 20252 Mar 2026 - Q2 sales and EBITDA rose, guidance increased, and net income jumped 31% on strong segment growth.TPB
Q2 20242 Feb 2026 - Q3 2024 saw double-digit profit growth, raised guidance, and expanded share buybacks.TPB
Q3 202415 Jan 2026 - FY2024 net sales up 11% and EBITDA up 12%, with strong modern oral and core brand growth.TPB
Q4 202416 Dec 2025 - Board recommends voting for all proposals, emphasizing diversity and governance improvements.TPB
Proxy Filing1 Dec 2025 - 2025 annual meeting moved to May 6 and will be held online; proposal deadlines updated.TPB
Proxy Filing1 Dec 2025 - Modern Oral sales soared 651%, driving 25% revenue growth and higher full-year guidance.TPB
Q2 202523 Nov 2025 - Q1 2025 net sales up 28.1%, net income up 19.8%, and Modern Oral sales guidance raised.TPB
Q1 202519 Nov 2025 - Modern Oral sales soared 628% year-over-year, driving record Q3 growth and raised guidance.TPB
Q3 202513 Nov 2025